Listen and follow our podcasts on:

This educational programme is supported by an Independent Educational Grant from Bayer

In this podcast HCC Experts Prof. Matthias Pinter and Prof. Jeroen Dekervel, discuss and debate the clinical implications of new HCC Phase 3 clinical trials data presented at the ILCA and ESMO congresses, 2022. They discuss Immuno-oncology agents and their place in the upcoming updated guidance such as the proposed new ILCA Systemic Therapies Guidance algorithm. They also discuss new treatment options in first line for advanced HCC presented at ESMO including the three late breaking abstracts LEAP-002, RATIONALE-301 and tislelizumab monotherapy trials. The latter two studying first-line treatment with an anti-PD1 antibody with or without a kinase inhibitor in patients with advanced hepatocellular carcinoma. The experts evaluate and provide their insights into how to integrate these new treatments for HCC in the clinical practice.

 

 

 

Dr Matthias Pinter works at the Medical University of Vienna in Austria where he also received both his MD and PhD. He is board-certified for Internal Medicine and Gastroenterology and Hepatology. Since 2017, he has led the hepatocellular carcinoma programme and research group at the Division of Gastroenterology and Hepatology at the Medical University of Vienna. His main research interests include the systemic treatment of liver cancer, particularly the identification of prognostic markers and scores that may help to identify patients most likely to benefit from specific therapies. To broaden his knowledge and expertise in basic research and experimental oncology, he worked as a research fellow and postdoc at renowned institutions, including the University of Bern in Switzerland and the Massachusetts General Hospital/Harvard Medical School in the United States. He has published numerous original papers and review articles on liver cancer in prestigious peer-reviewed journals covering the categories oncology, gastroenterology and hepatology, and radiology.

Assoc. Prof. Matthias Pinter has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Bayer, BMS, Ipsen, Eisai, Lilly, MSD and Roche.

Prof. Dr Jeroen Dekervel is a GI oncologist working at the Digestive Oncology Unit of UZ Leuven, Belgium. In daily clinical practice, he treats all kinds of gastrointestinal malignancies at one of the largest clinics of its kind in Europe. He is an associate professor at the KU Leuven, where his research focuses on unraveling the reasons for success and failure of immunotherapies in hepatocellular carcinoma, using a variety of single cell techniques. He is a member of ESMO and ASCO, as well as part of the ESMO upper GI faculty as a mentee.

Prof. Dr Jeroen Dekervel has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Bayer, Amgen, BMS, Eisai, Ipsen, Lilly, Merck, MSD, Roche, Novartis and Servier. 

Programme summary
Listen to the podcast now
Share this programme
This educational programme is supported by an Independent Educational Grant from Bayer
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
HCC CONNECT

HCC CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Bayer and Eisai Europe Limited.

Meet the experts Independent IME approved

Other programmes of interest

video Video
Oncology 
The emerging role of artificial intelligence in precision oncology

Expert opinion on the clinical application of artificial intelligence (AI)

Experts
Prof. Albrecht Stenzinger
  • download Downloadable
    Resources
  • clock 6 MIN
  • calendar Nov 2024

Educational programme supported by an Independent Educational Grant from Bayer.
podcast Podcast
Oncology 
BRAF-mutated CRC: from testing to treatment

Medical experts share insights and review key clinical trials

Experts
Prof. Sebastian Stintzing, Dr Thomas Winder
Endorsed by
Digestive Cancers Europe
  • download Downloadable
    Resources
  • clock 25 MIN
  • calendar Nov 2024

Educational programme supported by an Independent Educational Grant from Pierre Fabre. This content is not intended for HCPs within the UK.
other Other
Oncology 
Biomarker testing in NSCLC: patient and caregiver awareness and understanding

Findings from a global survey presented in a poster at ESMO 2024

Experts
Prof. Christian Rolfo, Prof. Fernando López-Ríos, Dr. Rodrigo Paredes, Amy Moore, Anne-Marie Baird, Shani Shilo
Endorsed by
LUNGevity
Lung Cancer Europe IASLC
The Israeli Lung Cancer Foundation ISLB
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Sep 2024

Educational programme supported by an Independent Educational Grant from Bayer.
podcast Podcast
  • download Downloadable
    Resources
  • clock 23 MIN
  • calendar Sep 2024

Educational programme supported by an Independent Educational Grant from Ipsen
conference-update Conference update
Oncology 
ESMO 2024: New data on GI, lung, HCC, breast and GU cancers

Renowned medical experts share their insights into new data presented at ESMO 2024

  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Sep 2024

animated-video Animated Video

Episode

1

of 1

episode
Oncology 
Precision oncology in prostate cancer: tips for optimal genomic testing

From sample collection through to diagnostic modalities 

Experts
Dr Alexander Wyatt
Endorsed by
AMP
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Sep 2024

Educational programme supported by an Independent Educational Grant from AstraZeneca and Amoy Diagnostics.